Cosciens Biopharma (CSCI) said Thursday it has started the phase 2a clinical efficacy study of its avenanthramides product, which it is developing for potential applications in managing conditions related to inflammation.

In phase 2a of the study, 20 patients with mild to moderate inflammation will participate. This phase is designed to assess potential efficacy in two arms with patients receiving selected doses of 480 mg and 960 mg per day, the company said. Initial dosing is expected to occur on March 14.

The Data Safety and Monitoring Board recommended initiating phase 2a after phase 1, done in November 2023, showed the favorable safety profile of the product, the company said.